Olumiant 2 mg film-coated tablets
Sponsors
Oslo University Hospital Hf, Centre Hospitalier Universitaire De Nantes, Assistance Publique Hopitaux De Paris, Centre Hospitalier Universitaire Rouen, Centre Hospitalier Universitaire Rouen, IRCCS Istituto Giannina Gaslini
Conditions
-women with an inflammatory HCA proven at histology and with at least one inflammatory HCA of more than 5 cm.
-male with at least one inflammatory HCA proven at histology whatever the size and considered as non resectable by the multidisciplinary tumor boardActive non-anterior non-infectious uveitisHIV-1 InfectionHospital-acquired pneumoniaHuman immunodeficency virusJuvenile idiopathic arthritisOsteoarthritisPolymyalgia Rheumatica (PMR)
Phase 2
Baricitinib for treating hospital-acquired pneumonia in critically ill patients with a proinflammatory phenotype, an international phase II / phase III, randomized, controlled trial - the TREAT-HAP study.
WithdrawnCTIS2023-503480-42-00
Target: 450Updated: 2023-07-03
JAKIH « A phase 2 open-label single-arm trial of JAK1 inhibitor for the treatment of large inflammatory hepatocellular adenomas »
RecruitingCTIS2023-505278-13-00
Start: 2024-10-01Target: 50Updated: 2024-11-06
Exploratory Phase 2 Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety and Impact on HIV-1 Reservoir of Baricitinib in Virologically Suppressed People With HIV-1
Not yet recruitingCTIS2024-520159-26-00
Target: 30Updated: 2025-05-09
Repurposed Drug Evaluation for Biological Aging, Pain, and Inflammation Reduction in Osteoarthritis
WithdrawnCTIS2025-524885-12-00
Target: 175Updated: 2026-05-26
Immunotherapy with a JAK1/JAK2 inhibitor (baricitinib) and an mTORC1 inhibitor (sirolimus), alone and in combination, for the control of HIV-1 replication after antiretroviral treatment interruption: a phase II multicenter, multi-arm, multi-stage, randomized, double-blind, placebo-controlled, adaptative trial
Not yet recruitingCTIS2025-523118-97-00
Target: 195Updated: 2026-10-27
Phase 3
European DisCoVeRy for Solidarity: An Adaptive Pandemic and Emerging Infection Platform Trial (SolidAct)
CompletedCTIS2022-500385-99-00
Start: 2021-06-03End: 2023-01-23Target: 2000Updated: 2023-01-30
Efficacy and Tolerance of Baricitinib, a JAK Inhibitor, in the Treatment of Refractory Non-infectious Non-anterior Uveitis (JAKUVEITE)
CompletedCTIS2024-513802-77-00
Start: 2023-08-30End: 2024-12-26Target: 33Updated: 2024-05-28
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-center, Phase III Study to Evaluate the Efficacy and Safety of Baricitinib as a Remission-Induction and Glucocorticoid-Sparing Regimen in Subjects with New-Onset Polymyalgia Rheumatica (JAK-SPARE 1)
Active, not recruitingCTIS2024-518556-22-00
Start: 2022-05-10Target: 46Updated: 2024-12-11
Justification AnD evaluation, in pOlymyalgia RhEumatica, of BARIcitinib versus placebo (JADORE-BARI study)
RecruitingCTIS2024-518385-26-01
Start: 2025-12-18Target: 140Updated: 2025-10-07
Phase 4
Toward personalized medicine to guide drug withdrawal in children with juvenile idiopathic arthritis in clinical remission: a randomized clinical trial comparing early versus late drug withdrawal combining imaging and multi-Omics.
RecruitingCTIS2024-514732-24-00
Start: 2025-04-28Target: 328Updated: 2025-08-26
REDO-JAK: Dose REDuction Of JAnus Kinase inhibitors in patients with inflammatory rheumatic diseases
RecruitingCTIS2025-520757-36-00
Start: 2025-09-15Target: 200Updated: 2026-01-13